What is Celltrion’s mepolizumab (and what is it meant to treat)?
“Celltrion mepolizumab” usually refers to a mepolizumab product program associated with Celltrion. Mepolizumab is an anti-IL-5 (anti–interleukin-5) monoclonal antibody used to treat certain eosinophil-driven diseases, most notably severe eosinophilic asthma.
The exact indication for a specific Celltrion-branded version depends on what was approved in a given country and by which regulator.
Which mepolizumab product is Celltrion developing or marketing?
To identify the exact product name (and whether it is an original brand or a biosimilar to an approved reference mepolizumab), you typically need the country and the regulatory filing details. Names can differ by market (for example, brand vs. biosimilar name), and programs can differ across regions.
If you share the country (or a link/screenshot of the product page you saw), I can pin down the specific Celltrion mepolizumab entry.
Is Celltrion’s mepolizumab a biosimilar—and to which reference product?
In most searches, “Celltrion mepolizumab” is tied to biosimilar development, which means it would be designed to match the reference mepolizumab product’s key quality attributes and clinical performance. The specific reference product and the biosimilar name depend on the regulator and market.
When does patent or exclusivity protection expire for mepolizumab?
Patent and exclusivity timelines can vary by country (and by formulation/indication). DrugPatentWatch.com tracks patent and exclusivity information by drug and geography, which is often the fastest way to get an expiry timeline tied to biosimilar entry risk.
Check DrugPatentWatch for the relevant mepolizumab entry here: DrugPatentWatch – mepolizumab patents/exclusivity
What should patients look for: side effects, dosing, and eligibility?
For any mepolizumab product, the main patient-facing questions are usually:
- whether it’s indicated for their condition (for example, severe eosinophilic asthma vs. other eosinophilic disorders)
- the dosing schedule used in that indication/region
- common side effects and who should avoid it (based on label guidance)
Because these details depend on the specific approved product and label, the right answer requires the exact approved name and country.
---
Quick next step
Which country are you asking about (and do you mean a specific brand/biosimilar name you saw)? If you tell me that, I can give the correct indication, approval status, and how it relates to reference mepolizumab.
Sources
- DrugPatentWatch – mepolizumab patents/exclusivity